Below are the most recent publications written about "Urinary Bladder Neoplasms" by people in Profiles.
-
Sangoi AR, Shahabi A, Hirsch MS, Kao CS, Deebajah M, Barletta JA, Paner GP, Smith SC, Grignon DJ, Comp?rat E, Amin MB, Maclean F, Shah RB, Iczkowski KA, Delprado W, Cheng L, Pan CC, McKenney JK, Ro JY, Khani F, Montironi R, Robinson BD, Al-Ahmadie H, Epstein JI, Trpkov K, Tretiakova M, Shen SS, Alanee S, Weight CJ, Akgul M, Williamson SR. Urothelial carcinoma in situ with "early papillary formation" vs "lateral spread/shoulder lesion" of prior high-grade noninvasive papillary urothelial carcinoma: A survey of pathologist and urologist interpretations. Am J Clin Pathol. 2025 Apr 19; 163(4):629-640.
-
Johnson BA, Parimi V, Kamanda S, Corney DC, Choi W, Hoffman-Censits J, Kates M, McConkey DJ, Hahn NM, Matoso A. Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells. J Pathol Clin Res. 2025 Mar; 11(2):e70021.
-
Zarrabi KK, Saxena A, Mouw KW, Koshkin VS, Friedlander T. Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma. Am Soc Clin Oncol Educ Book. 2025 Jan; 45(2):e471924.
-
Pallauf M, Br?nimann S, Rezaee ME, Kohn TP, Fletcher SA, McNamara M, Enikeev D, Shariat SF, Hoffman-Censits J, Smith AK, Singla N. Metformin intake and risk of metabolic acidosis after radical cystectomy with urinary diversion: A comparative study using data from the TriNetX research network. Urol Oncol. 2025 07; 43(7):441.e11-441.e18.
-
Daneshmand S, Kamat AM, Shore ND, Meeks JJ, Galsky MD, Jacob JM, van der Heijden MS, Williams SB, Powles T, Chang SS, Catto JWF, Psutka SP, Guerrero-Ramos F, Xylinas E, Miyake M, Simone G, Daniel K, Sweiti H, Cutie C, Necchi A. Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer. Urol Oncol. 2025 05; 43(5):286-296.
-
Downs TM, Bailey HH, Lozar T, Schmitz NS, Green H, Scarlett CO, Havighurst TC, Twaroski K, DeShong K, Wollmer B, Bivalacqua TJ, Saltzstein DR, Shore N, Kim K, Huang W, Ricke WA, Barroilhet L, House M, Parnes HL, Messing E. Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery. Cancer Prev Res (Phila). 2025 Jan 06; 18(1):31-39.
-
Simhal RK, McPartland C, Wang KR, Buck M, Shah YB, Poluch ML, Hochberg AR, Im BH, Chandrasekar T, Shah MS, Lallas CD. Bowel regimens before radical cystectomy: An analysis of a modern cohort. Int J Urol. 2025 Apr; 32(4):402-408.
-
Geynisman DM, Abbosh PH, Ross E, Zibelman MR, Ghatalia P, Anari F, Mark JR, Stamatakis L, Hoffman-Censits JH, Viterbo R, Greenberg RE, Churilla TM, Horwitz EM, Hallman MA, Smaldone MC, Uzzo R, Chen DYT, Kutikov A, Plimack ER. Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). J Clin Oncol. 2025 Mar 20; 43(9):1113-1122.
-
Leyderman M, Chandrasekar T, Grivas P, Li R, Bhat S, Basnet A, Shapiro O, Jacob J, Daneshvar MA, Kord E, Bratslavsky G, Goldberg H. Metastasis development in non-muscle-invasive bladder cancer. Nat Rev Urol. 2025 Jun; 22(6):375-386.
-
Buraschi S, Xu SQ, Stefanello M, Moskalev I, Morcavallo A, Genua M, Tanimoto R, Birbe R, Peiper SC, Gomella LG, Belfiore A, Black PC, Iozzo RV, Morrione A. Correction: Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin. Oncotarget. 2024 10 01; 15:697-698.